Bora Pharmaceuticals Co (TPE:6472) Beneish M-Score: -2.51 (As of Jul. 05, 2026)


TPE:6472 Bora Pharmaceuticals Co Ltd TPE:6472
87 GF Score
Price NT$439.50
GF Value NT$716.94
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Bora Pharmaceuticals Co Beneish M-Score?

Bora Pharmaceuticals Co TPE:6472 +1.74% 87 Beneish M-Score is -2.51 as of Jul. 05, 2026. GuruFocus rates TPE:6472 with a GF Score™ of 87/100 and a GF Value™ of NT$716.94 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 907 Drug Manufacturers companies, Bora Pharmaceuticals Co ranks better than 51.27% on this metric.

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.51 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for Bora Pharmaceuticals Co's Beneish M-Score or its related term are showing as below:

TPE:6472' s Beneish M-Score Range Over the Past 10 Years
Min: -2.76   Med: -1.71   Max: 1.23
Current: -2.51

During the past 13 years, the highest Beneish M-Score of Bora Pharmaceuticals Co was 1.23. The lowest was -2.76. And the median was -1.71.


Bora Pharmaceuticals Co Beneish M-Score Historical Data

* Premium members only.

The historical data trend for Bora Pharmaceuticals Co's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bora Pharmaceuticals Co Beneish M-Score Chart

Bora Pharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.30 1.16 -2.76 -1.18 -2.51

Bora Pharmaceuticals Co Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.18 -0.94 -2.19 -2.20 -2.51

TPE:6472 vs ZTS, UTHR: Beneish M-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bora Pharmaceuticals Co's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bora Pharmaceuticals Co Beneish M-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bora Pharmaceuticals Co's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Bora Pharmaceuticals Co's Beneish M-Score falls into.


TPE:6472
87GF Score
Bora Pharmaceuticals Co Ltd TPE:6472
Beneish M-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bora Pharmaceuticals Co Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Bora Pharmaceuticals Co for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.7826+0.528 * 1.0824+0.404 * 1.5012+0.892 * 1.0911+0.115 * 0.8562
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 1.0341+4.679 * -0.034045-0.327 * 0.9102
=-2.51

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec25) TTM:Last Year (Dec24) TTM:
Total Receivables was NT$9,604 Mil.
Revenue was 4860.654 + 4806.145 + 4867.785 + 4479.585 = NT$19,014 Mil.
Gross Profit was 1772.261 + 2171.873 + 2019.383 + 1889.497 = NT$7,853 Mil.
Total Current Assets was NT$19,338 Mil.
Total Assets was NT$44,714 Mil.
Property, Plant and Equipment(Net PPE) was NT$11,183 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$1,087 Mil.
Selling, General, & Admin. Expense(SGA) was NT$3,886 Mil.
Total Current Liabilities was NT$13,321 Mil.
Long-Term Debt & Capital Lease Obligation was NT$12,505 Mil.
Net Income was 331.759 + 633.61 + 616.669 + 1399.273 = NT$2,981 Mil.
Non Operating Income was 0 + 0 + 0 + 0 = NT$0 Mil.
Cash Flow from Operations was 1229.115 + 569.503 + 1360.014 + 1344.957 = NT$4,504 Mil.
Total Receivables was NT$11,248 Mil.
Revenue was 5124.686 + 5027.239 + 4417.206 + 2857.493 = NT$17,427 Mil.
Gross Profit was 1979.935 + 2337.39 + 1967.221 + 1505.99 = NT$7,791 Mil.
Total Current Assets was NT$23,377 Mil.
Total Assets was NT$45,510 Mil.
Property, Plant and Equipment(Net PPE) was NT$12,510 Mil.
Depreciation, Depletion and Amortization(DDA) was NT$1,026 Mil.
Selling, General, & Admin. Expense(SGA) was NT$3,444 Mil.
Total Current Liabilities was NT$13,808 Mil.
Long-Term Debt & Capital Lease Obligation was NT$15,070 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(9604.483 / 19014.169) / (11247.884 / 17426.624)
=0.505122 / 0.645443
=0.7826

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(7790.536 / 17426.624) / (7853.014 / 19014.169)
=0.447048 / 0.413009
=1.0824

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (19337.605 + 11183.144) / 44714.187) / (1 - (23377.193 + 12509.753) / 45509.645)
=0.317426 / 0.211443
=1.5012

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=19014.169 / 17426.624
=1.0911

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(1026.329 / (1026.329 + 12509.753)) / (1086.557 / (1086.557 + 11183.144))
=0.075822 / 0.088556
=0.8562

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(3885.518 / 19014.169) / (3443.661 / 17426.624)
=0.204349 / 0.197609
=1.0341

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((12505.181 + 13320.926) / 44714.187) / ((15069.854 + 13807.98) / 45509.645)
=0.577582 / 0.634543
=0.9102

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(2981.311 - 0 - 4503.589) / 44714.187
=-0.034045

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Bora Pharmaceuticals Co has a M-score of -2.51 suggests that the company is unlikely to be a manipulator.

Frequently Asked Questions Learn more about Beneish M-Score →
What does a Beneish M-Score of -2.51 mean?
Bora Pharmaceuticals Co (TPE:6472) has a Beneish M-Score of -2.51 as of Jul. 05, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bora Pharmaceuticals Co and its competitors. According to the industry distribution chart, Bora Pharmaceuticals Co ranks #442 out of 907 companies in the Drug Manufacturers industry, placing it in the top 48.7%.
Is Bora Pharmaceuticals Co's Beneish M-Score too high?
Bora Pharmaceuticals Co's current Beneish M-Score is -2.51. Based on the distribution chart, Bora Pharmaceuticals Co ranks #442 out of 907 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Bora Pharmaceuticals Co has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bora Pharmaceuticals Co's Beneish M-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Bora Pharmaceuticals Co ranks #442 out of 907 companies for Beneish M-Score. This puts Bora Pharmaceuticals Co in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Drug Manufacturers company?
A good Beneish M-Score depends on the Drug Manufacturers industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Bora Pharmaceuticals Co and its competitors. Bora Pharmaceuticals Co's current Beneish M-Score is -2.51. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bora Pharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Bora Pharmaceuticals Co (TPE:6472) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$716.94, compared to a current price of NT$439.50 — trading 38.7% below its estimated fair value. The current Beneish M-Score is -2.51. Bora Pharmaceuticals Co's overall GF Score™ is 87/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Bora Pharmaceuticals Co (TPE:6472), the current Beneish M-Score is -2.51 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bora Pharmaceuticals Co (TPE:6472) Overvalued in 2026?

Based on GuruFocus' analysis, Bora Pharmaceuticals Co stock appears to be undervalued. The current stock price of NT$439.50 is trading 38.7% below its estimated GF Value™ of NT$716.94. GuruFocus considers Bora Pharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for TPE:6472:

  • Beneish M-Score: -2.51
  • GF Value™: NT$716.94 vs. price of NT$439.50 (38.7% below fair value)
  • GF Score™: 87/100 with 4 warning signs

No single metric tells the full story. See the TPE:6472 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Bora Pharmaceuticals Co Business Description

Address No. 2, Aly. 36, Lane 26, Ruiguang Road, 6th Floor, Neihu District, Taipei, TWN, 114
Bora Pharmaceuticals Co Ltd is a pharmaceutical company based in Taiwan. It covers the pharmaceutical supply chain from research and development to sales and distribution. The main activities of the Company focus on manufacturing and selling generic, brand, and over-the-counter (OTC) drugs, contract development and manufacturing (CDMO), and developing and selling consumer healthcare products. The Group operates in three reportable segments; Sales segment: sale of pharmaceuticals, generics, and healthcare products. CDMO segment: contract development and manufacturing organization of pharmaceuticals. Other segment: Others. Geographically, the company operates in the USA which derives key revenue, Europe, Taiwan, and other regions.
87GF Score

Get the complete analysis for TPE:6472

Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$439.50
Price
NT$716.94
GF Value